Drug Profile
IPL 512602
Alternative Names: AVE 0547; IPL 512,602Latest Information Update: 07 Feb 2017
Price :
$50
*
At a glance
- Originator Inflazyme Pharmaceuticals
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Small molecules
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Allergic rhinitis; Asthma
Most Recent Events
- 07 Feb 2017 Discontinued - Phase-II for Asthma in Russia, Ukraine, Eastern Europe, USA (PO)
- 07 Feb 2017 Discontinued - Preclinical for Allergic rhinitis in North America (PO)
- 29 Jan 2007 Inflazyme completes the phase IIb CAPSICS trial for Asthma in the US, Eastern Europe, Russia and Ukraine